IP Library › Granted Patent US 12,234,296
Granted Patent B2
US 12,234,296 · App. 18/087,393 · Granted Feb 25, 2025

Sickled beta globin antibodies

Inventor: Olivier Negre (Somerville, MA)
Assignee: bluebird bio, Inc.
C07K16/34C07K2317/565C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,296
App. No.
18/087,393
Granted
Feb 25, 2025
Kind
B2
Abstract

The invention provides anti-β S globin antibodies or antigen binding fragments thereof.

Claims (6)

1. An anti-β S globin antibody or antigen binding fragment thereof that binds a human β S globin polypeptide, wherein the anti-β S globin antibody or antigen binding fragment thereof comprises a light chain variable region comprising CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3) and a heavy chain variable region comprising CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6).

2. The anti-β S globin antibody or antigen binding fragment thereof of claim 1 , wherein the anti-β S globin antibody or antigen binding fragment that binds the human β S globin polypeptide is an scFv.

3. A conjugate, comprising the anti-β S globin antibody or antigen binding fragment thereof of claim 1 ; and a detectable label.

4. The conjugate of claim 3 , wherein the detectable label is selected from the group consisting of: a hapten, a fluorescent dye, a fluorescent protein, a chromophore, a metal ion, a gold particle, a silver particle, a magnetic particle, a polypeptide, an enzyme, a luminescent compound, or an oligonucleotide.

5. A hybridoma comprising the anti-β S globin antibody of claim 1 .

6. A polynucleotide encoding the anti-β S globin antibody or antigen binding fragment thereof of claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Sep 25, 2025
From: BLUEBIRD BIO, INC.
To: GENETIX BIOTHERAPEUTICS INC.
Reel/Frame 072955/0154 →
SECURITY INTEREST Recorded Mar 15, 2024
From: BLUEBIRD BIO, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 066801/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2023
From: NEGRE, OLIVIER
To: BLUEBIRD BIO, INC.
Reel/Frame 064044/0788 →
Continuity (3)
Continuation 16771411
Provisional Application 62599260 · Dec 15, 2017
Related Publication 20230279145A1 · Sep 7, 2023
References Cited (24)
US 4752583A · Jensen et al. · 1988 [cited by applicant]
US 11535681B2 · Negre · 2022 [cited by applicant]
US 20110117670A1 · Walker et al. · 2011 [cited by applicant]
US 20160116489A1 · Cao et al. · 2016 [cited by applicant]
WO 2017139478A1 · 2017 [cited by applicant]
Kiprivanov et al., Mol Biotechnol. Jan. 2004;26(1):39-60. doi: 10.1385/MB:26:1:39. PMID: 14734823. [cited by examiner]
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J Immunol, Jul. 1, 1991, 147 (1) 86-95. [cited by applicant]
Brodeur et al., “Monoclonal Antibody Production Techniques and Applications,” pp. 51-63 (Marcel Dekker, Inc., New York, 1987). [cited by applicant]
Bruggemann et al., “Designer mice: the production of human antibody repertoires in transgenic animals,” Year in Immunol., 7: 33-40 (1993). [cited by applicant]
Curd et al., “Antibodies to an NH2-terminal fragment of betaS globin. II. Specificity and isolation of antibodies for the sickle mutation.,” J Biol Chem. Mar. 10, 1976;251(5):1290-5. [cited by applicant]
Edwards et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS,” J Mol Biol. Nov. 14, 2003;334(1):103-18. [cited by applicant]
Goel et al., “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response,” J Immunol. Dec. 15, 2004;173(12):7358-67. [cited by applicant]
International Search Report and Written Opinion dated Mar. 11, 2019, for International Application No. PCT/US2018/065782, 8 pages. [cited by applicant]
Jakobovits et al., “Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production,” PNAS Mar. 15, 1993, 90 (6) 2551-2555. [cited by applicant]
Jakobovits et al., “Germ-line transmission and expression of a human-derived yeast artificial chromosome,” Nature, 362: 255 (1993). [cited by applicant]
Janeway et al., Immunobiology, 3rd edition, 1997 Garland Publishing Inc., pp. 3:1-3:11. [cited by applicant]
Kanyavuz et al., “Breaking the law: unconventional strategies for antibody diversification,” Nat Rev Immunol. Jun. 2019;19(6):355-368. doi: 10.1038/S41577-019-0126-7. [cited by applicant]
Kozbor et al., “A human hybrid myeloma for production of human monoclonal antibodies,” J Immunol Dec. 1, 1984, 133 (6) 3001-3005. [cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Eng Des Sel. Mar. 2009;22(3):159-68. doi: 10.1093/… [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/771,411 dated May 5, 2022. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/771,411 dated Aug. 29, 2022. [cited by applicant]
Plückthun, “Antibodies from [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA. Mar. 1982;79(6):1979-83. [cited by applicant]
Young et al., “The NH2-terminal Region of the Sickle Hemoglobin ß Chain,” The Journal of Biological Chemistry, Oct. 25, 1976, vol. 251, No. 20, pp. 6431-6438. [cited by applicant]